Abstract
Plants are gaining increasingly acceptance as a production platform for recombinant proteins. One reason for this is their ability to carry out posttranslational protein modifications in a similar if not identical way as mammalian cells. The capability of plants to carry out human-like complex glycosylation is well known. Moreover, the targeted manipulation of the plant N-glycosylation pathway allows the production of proteins carrying largely homogeneous, human-type oligosaccharides. These outstanding results have placed plants in a favourable position compared to other eukaryotic expression systems. This review provides a comprehensive summary of the N-glycosylation of plant-produced recombinant proteins, the possible impact of plant-specific N-glycans on the human immune system, and recent advances in engineering the plant N-glycosylation pathway towards the synthesis of (complex) human-type glycan structures, highlighting challenges and achievements in the application of these powerful technologies
Original language | English |
---|---|
Pages (from-to) | 5503-5512 |
Journal | Current Pharmaceutical Design |
Volume | 19 |
Issue number | 31 |
DOIs | |
Publication status | Published - 2013 |
Keywords
- reactive carbohydrate determinants
- human monoclonal-antibody
- sialic acid transporter
- arabidopsis-thaliana
- transgenic plants
- storage vacuoles
- endoplasmic-reticulum
- high-level
- beta-1,4-n-acetylglucosaminyltransferase iii
- human beta-1,4-galactosyltr